Larson Financial Group’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $7.82M | Buy |
35,942
+6,828
| +23% | +$1.51M | 0.25% | 78 |
|
|
2025
Q4 | $6.65M | Buy |
29,114
+2,858
| +11% | +$651K | 0.22% | 85 |
|
|
2025
Q3 | $6.08M | Buy |
26,256
+1,987
| +8% | +$405K | 0.21% | 92 |
|
|
2025
Q2 | $4.5M | Buy |
24,269
+850
| +4% | +$158K | 0.18% | 113 |
|
|
2025
Q1 | $4.91M | Sell |
23,419
-480
| -2% | -$93.3K | 0.23% | 84 |
|
|
2024
Q4 | $4.25M | Buy |
23,899
+5,087
| +27% | +$935K | 0.22% | 89 |
|
|
2024
Q3 | $3.72M | Buy |
18,812
+2,680
| +17% | +$500K | 0.21% | 96 |
|
|
2024
Q2 | $2.77M | Buy |
16,132
+10,792
| +202% | +$1.79M | 0.19% | 98 |
|
|
2024
Q1 | $972K | Buy |
5,340
+2,505
| +88% | +$432K | 0.08% | 172 |
|
|
2023
Q4 | $439K | Buy |
2,835
+305
| +12% | +$44.5K | 0.04% | 233 |
|
|
2023
Q3 | $377K | Buy |
2,530
+536
| +27% | +$78.7K | 0.04% | 229 |
|
|
2023
Q2 | $269K | Sell |
1,994
-19
| -0.9% | -$2.79K | 0.03% | 271 |
|
|
2023
Q1 | $321K | Buy |
2,013
+243
| +14% | +$37.2K | 0.03% | 250 |
|
|
2022
Q4 | $286K | Buy |
1,770
+16
| +0.9% | +$2.45K | 0.03% | 252 |
|
|
2022
Q3 | $235K | Sell |
1,754
-3,037
| -63% | -$436K | 0.03% | 255 |
|
|
2022
Q2 | $734K | Sell |
4,791
-478
| -9% | -$73K | 0.13% | 82 |
|
|
2022
Q1 | $854K | Sell |
5,269
-161
| -3% | -$23.4K | 0.14% | 80 |
|
|
2021
Q4 | $735K | Sell |
5,430
-318
| -6% | -$37.6K | 0.12% | 87 |
|
|
2021
Q3 | $620K | Buy |
5,748
+5,085
| +767% | +$581K | 0.12% | 72 |
|
|
2021
Q2 | $75K | Buy |
663
+7
| +1% | +$788 | 0.02% | 212 |
|
|
2021
Q1 | $71K | Buy |
656
+22
| +3% | +$2.35K | 0.02% | 206 |
|
|
2020
Q4 | $68K | Buy |
634
+7
| +1% | +$673 | 0.02% | 174 |
|
|
2020
Q3 | $55K | Sell |
627
-11
| -2% | -$1.04K | 0.02% | 185 |
|
|
2020
Q2 | $63K | Buy |
638
+230
| +56% | +$20.3K | 0.03% | 167 |
|
|
2020
Q1 | $31K | Sell |
408
-11
| -3% | -$937 | 0.02% | 189 |
|
|
2019
Q4 | $37K | Sell |
419
-283
| -40% | -$23.5K | 0.02% | 171 |
|
|
2019
Q3 | $53K | Buy |
702
+229
| +48% | +$15.7K | 0.03% | 141 |
|
|
2019
Q2 | $34K | Buy |
473
+71
| +18% | +$5.58K | 0.03% | 148 |
|
|
2019
Q1 | $32K | Buy |
402
+5
| +1% | +$409 | 0.03% | 138 |
|
|
2018
Q4 | $37K | Buy |
+397
| New | +$34.9K | 0.03% | 126 |
|
Other funds holding ABBV
VCM
VPM
Larson Financial Group's ABBV Position: Q1 2026 in Review
Larson Financial Group increased its AbbVie (ABBV) stake by 23% in Q1 2026, buying an estimated $1.51M and bringing the position to 35,942 shares worth $7.82M. The position accounts for 0.25% of the portfolio, ranked #78.
Larson Financial Group first reported a position in ABBV in Q4 2018 and has held it in 30 quarters since. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- Larson Financial Group held 35,942 shares of AbbVie worth $7.82M as of Q1 2026.
- Larson Financial Group bought 6,828 AbbVie shares in Q1 2026, an estimated $1.51M.
- AbbVie made up 0.25% of Larson Financial Group's portfolio in Q1 2026, its #78 holding.
- Larson Financial Group first reported a position in AbbVie in Q4 2018 and has held it in 30 quarters since.
- 4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on Larson Financial Group's 13F filing for Q1 2026, filed 15 May 2026.